CMS Heart Failure Reimbursement 
DAIC
MARCH 13, 2024
CMS has reviewed the CardiAMP Heart Failure II Trial and approved the investigational product, related and routine items and services for purposes of Medicare coverage. The CardiAMP Heart Failure II Trial is FDA approved to enroll up to 250 patients at up to 40 clinical centers. said Peter Altman , PhD.,
DAIC
MARCH 7, 2024
Results showed reductions in heart death equivalents and MACCE, with a magnified reduction among patients with elevated NTproBNP, a common marker of heart distress. These patients saw more than a 17% lower rate of heart death equivalents at up to two years compared to control patients treated with heart failure medication alone (2.9%
DAIC
JULY 25, 2024
FDA granted CardiAMP Cell Therapy a Breakthrough Device Designation for the treatment of ischemic heart failure. Leslie Miller, MD , trial investigator at the CHF Heart Function Clinic at BayCare Morton Plant Hospital in Clearwater, Florida and a member of the CardiAMP Heart Failure II Study Executive Steering Committee. “As
American College of Cardiology
FEBRUARY 1, 2025
In today's health care landscape, where quality metrics tied to reimbursement have become the standard, clinicians are under increasing pressure to prescribe specific medications. Drugs That May Cause or Exacerbate Heart Failure: A Scientific Statement from the American Heart Association. BMC Med2015;13(74). Circulation.
CardiacWire
DECEMBER 10, 2023
A new study in European Heart Journal – Digital Health showed that Us2.ai’s ai’s AI echo algorithm can interpret echocardiographic strain images with similar accuracy as conventional measurements, highlighting how AI can democratize cardiac strain exams and improve heart failure assessments. in Taiwanese cohort; −15.4
Expert insights. Personalized for you.
111 
Let's personalize your content